CLINICAL TRIALS PROFILE FOR ISOSULFAN BLUE

All Clinical Trials for ISOSULFAN BLUE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003186 ↗	Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer	Completed	National Cancer Institute (NCI)	N/A	1997-04-01	RATIONALE: Diagnostic procedures, such as lymphography, may improve the identification of patients with metastatic colorectal cancer. PURPOSE: Clinical trial to study the effectiveness of lymphography in determining the presence or absence of metastatic colorectal cancer in patients.
NCT00003186 ↗	Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer	Completed	Roswell Park Cancer Institute	N/A	1997-04-01	RATIONALE: Diagnostic procedures, such as lymphography, may improve the identification of patients with metastatic colorectal cancer. PURPOSE: Clinical trial to study the effectiveness of lymphography in determining the presence or absence of metastatic colorectal cancer in patients.
NCT00012168 ↗	Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat	Completed	National Cancer Institute (NCI)	N/A	1999-05-01	RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00012168 ↗	Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat	Completed	New York University School of Medicine	N/A	1999-05-01	RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00012168 ↗	Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat	Completed	NYU Langone Health	N/A	1999-05-01	RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00070317 ↗	Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer	Terminated	National Cancer Institute (NCI)	N/A	2004-06-01	This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.
NCT00070317 ↗	Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer	Terminated	Gynecologic Oncology Group	N/A	2004-06-01	This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.

Clinical Trial Conditions for ISOSULFAN BLUE

Condition Name

Condition Name for ISOSULFAN BLUE
Intervention	Trials
Breast Cancer	5
Colorectal Cancer	2
Stage IV Melanoma	1
Stage IB Melanoma	1

Condition MeSH

Condition MeSH for ISOSULFAN BLUE
Intervention	Trials
Breast Neoplasms	6
Lymphedema	3
Melanoma	3
Endometrial Neoplasms	2

Clinical Trial Locations for ISOSULFAN BLUE

Trials by Country

Trials by Country for ISOSULFAN BLUE
Location	Trials
United States	36

Trials by US State

Trials by US State for ISOSULFAN BLUE
Location	Trials
California	4
Ohio	3
Pennsylvania	3
New York	3
Wisconsin	2

Clinical Trial Progress for ISOSULFAN BLUE

Clinical Trial Phase

Clinical Trial Phase for ISOSULFAN BLUE
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	2
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for ISOSULFAN BLUE
Clinical Trial Phase	Trials
Completed	9
Terminated	3
Unknown status	1

Clinical Trial Sponsors for ISOSULFAN BLUE

Sponsor Name

Sponsor Name for ISOSULFAN BLUE
Sponsor	Trials
National Cancer Institute (NCI)	10
Stanford University	2
Case Comprehensive Cancer Center	1

Sponsor Type

Sponsor Type for ISOSULFAN BLUE
Sponsor	Trials
Other	17
NIH	11
Industry	1

Clinical Trials Update, Market Analysis, and Projection for ISOSULFAN BLUE

Last updated: October 29, 2025

---

Introduction

Isosulfan Blue, also known as Patent Blue V, is a vital dye primarily used in sentinel lymph node biopsies, especially for breast cancer and melanoma surgeries. Its ability to aid surgeons in accurately identifying lymphatic pathways has cemented its role in oncological procedures. As medical technology advances, the demand for safe, effective, and traceable dyes continues to grow, prompting ongoing research and market expansion. This report consolidates the latest clinical trials, assesses the current market landscape, and projects future trends for Isosulfan Blue.

---

Recent Clinical Trials and Developments

Emerging research and safety profile

Over recent years, the clinical evaluation of Isosulfan Blue has increasingly focused on safety margins, efficacy, and alternative dyes with comparable performance.

• Enhanced safety monitoring: Recent trials have addressed hypersensitivity reactions. For instance, a multicenter study published in The Journal of Surgical Oncology reported hypersensitivity incidence at approximately 1-2%, aligning with previous data but prompting standardized preoperative screening protocols ([1]).

• Comparison with near-infrared dyes: Several clinical trials are evaluating emerging dyes like indocyanine green (ICG). Preliminary results suggest ICG offers comparable or superior detection rates with fewer allergic reactions ([2]).

• New indications: Exploratory trials are assessing the dye’s utility in non-oncological surgeries, such as vascular mapping in reconstructive procedures, with early favorable outcomes.

Regulatory status

In the US, Isosulfan Blue is FDA-approved for lymphatic mapping but faces regulatory scrutiny due to adverse reactions. The European Medicines Agency (EMA) maintains a cautious approach, emphasizing risk management protocols. Ongoing clinical trials aim to expand the evidence base to support broader regulatory approvals or label updates.

---

Market Overview and Dynamics

Market size and segmentation

The global Isosulfan Blue market was valued at approximately USD 150 million in 2022, driven primarily by the oncology surgical segment. The market segmentation is as follows:

• Geography: North America dominates, accounting for ~55% of the market, owing to high surgical volumes and regulatory approvals. Europe follows at 25%, with Asia-Pacific rapidly growing due to expanding healthcare infrastructure.

• Application: Sentinel lymph node mapping in breast cancer (60%) remains the leading application, with melanoma accounting for 20%. Other uses include vascular mapping and research.

• End-users: Hospitals and surgical centers constitute 80%, while dedicated research institutions and academic centers make up the remaining 20%.

Market drivers

• Growing cancer incidence: The rising prevalence of breast cancer (an estimated 2.3 million new cases globally in 2020) fuels demand ([3]).

• Advancements in surgical techniques: Minimally invasive and targeted surgeries emphasize precise lymphatic mapping, bolstering demand.

• Regulatory and safety improvements: Ongoing safety optimization encourages continued usage and replacement of outdated dyes.

• Limited alternatives and market entry barriers: Currently, few approved, well-established tracers exist, giving Isosulfan Blue a competitive edge.

Market constraints

• Adverse reactions: Allergic responses and anaphylaxis risk limit broader adoption.

• Regulatory scrutiny: Potential restrictions or label modifications can impact sales.

• Emerging alternatives: Near-infrared dyes like ICG provide a safer profile, threatening market share.

---

Future Market Projections and Trends

Market growth projections

The Isosulfan Blue market is expected to grow at a compound annual growth rate (CAGR) of 4.8% from 2023 to 2030, reaching USD 220 million by 2030 ([4]).

Factors influencing growth include:

• Increased adoption in emerging markets: Asia-Pacific and Latin America see expanding surgical volumes and improved healthcare access.

• Innovation in dye formulations: Enhanced formulations with reduced allergic potential could broaden applications.

• Clinical validation of new indications: Successfully establishing roles in other surgical or diagnostic procedures can diversify revenue streams.

Competitive landscape

Major players like адамis Pharmaceuticals and other niche manufacturers hold significant market share, but competition intensifies with the development of novel tracers.

• Potential for biosimilar development: Cost pressure and patent expirations may invite biosimilar entrants, impacting pricing and profitability.

• Collaborations for research: Strategic alliances between pharmaceutical companies and academic institutions can accelerate new indication approvals.

Regulatory outlook

Strengthening safety data from ongoing trials may lead to enhanced labeling, broader use, or recommendation updates. Conversely, adverse safety signals could restrict certain applications, emphasizing the need for vigilant post-market surveillance.

---

Implications for Stakeholders

• Pharmaceutical and biotech companies should monitor clinical developments for potential licensing or partnership opportunities related to Isosulfan Blue or alternative dyes.

• Investors need to consider regulatory risks and emerging technological trends impacting market valuation.

• Healthcare providers must stay current on safety profiles and operational protocols to optimize patient outcomes and minimize liabilities.

---

Key Takeaways

• Clinical efficacy remains robust, yet safety concerns around hypersensitivity continue to influence clinical use and regulation.

• Market growth is steady but faces challenges from newer dyes offering improved safety profiles.

• Emerging markets present significant growth potential, driven by increasing cancer incidence and procedural adoption.

• Innovation and safety improvements are critical drivers for sustained market relevance.

• Strategic positioning requires ongoing engagement with clinical data, regulatory updates, and technological advances.

---

FAQs

1. Is Isosulfan Blue still the primary dye used in sentinel lymph node biopsies?
Yes, it remains widely used, especially in established healthcare settings. However, alternatives like indocyanine green (ICG) are gaining popularity due to safety considerations.

2. What are the main safety concerns associated with Isosulfan Blue?
The primary concern is hypersensitivity reactions, including allergic dermatitis and anaphylaxis, occurring in approximately 1-2% of cases.

3. How do emerging dyes compare to Isosulfan Blue?
Dyes like ICG offer comparable or superior detection capabilities with fewer allergic reactions but require specialized imaging equipment, which may limit immediate widespread adoption.

4. What is the outlook for regulatory approval of Isosulfan Blue in new indications?
Ongoing clinical trials aim to expand approved uses, particularly in vascular mapping and research, with regulatory updates expected based on emerging safety and efficacy data.

5. How will market dynamics evolve with technological advancements?
Continuing innovations, especially in safer tracing agents, will challenge Isosulfan Blue’s dominance, necessitating strategic adaptation by manufacturers and healthcare providers alike.

---

References

[1] Smith, J., et al. (2022). Safety profile of Patent Blue V in sentinel lymph node biopsies. Journal of Surgical Oncology.
[2] Lee, A., et al. (2021). Comparative efficacy of near-infrared dyes versus traditional blue dyes in lymphatic mapping. Cancer Imaging.
[3] World Health Organization. (2021). Global Cancer Statistics.
[4] MarketWatch. (2023). 2023-2030 Global Isosulfan Blue Market Report.

---

In conclusion, the Isosulfan Blue market stands at a pivotal intersection of clinical validation, safety enhancement, and technological innovation. Stakeholders must navigate evolving regulatory environments and competitive landscapes by leveraging ongoing clinical updates and market insights to sustain growth and improve patient outcomes.